DMAC · CIK 0001401040
What DiaMedica Therapeutics Inc. told the SEC could break it.
DiaMedica's disclosures describe a pre-revenue biotech whose prospects rest on one candidate, DM199, and a thin chain supporting it. It has a single source of supply for both drug substance and drug product, leaving it little leverage with its manufacturer and exposed to supply or pricing disruption. It funds operations through equity — a July 2025 $30.1 million private placement and an up-to-$100 million at-the-market program — creating dilution and financing risk, and it runs its pivotal trials outside the U.S. (South Africa, Canada, Georgia, the UK and EU), where the FDA may impose conditions on or decline to accept the foreign data, jeopardizing approval.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single source of supply for DM199 drug substance and drug producthigh
DiaMedica has a single source of supply for both its drug substance and drug product, minimizing leverage with its CDMO and exposing it to pricing and supply disruption.
“We currently have a single source of supply for our drug substance and for our drug product.”
SEC filing →As of 2026
Liquidity & debt
- pre-revenue reliance on equity financing (private placements, $100M ATM)medium
Pre-revenue DiaMedica funds operations through equity — a July 2025 $30.1M private placement and an August 2025 up-to-$100M ATM program with TD Cowen — exposing shareholders to dilution and financing risk.
“On August 12, 2025, we entered into a Sales Agreement (the 2025 Sales Agreement) with TD Securities (USA) LLC (TD Cowen) under which the Company may, from time to time, sell common shares having an aggregate offering price of up to $ 100 million, through an “at-the-market” offering program (ATM Offering).”
SEC filing →As of 2026
Regulatory & policy
- FDA acceptance of foreign clinical trial data (South Africa, Canada, Georgia, UK, EU)medium
DiaMedica conducts pivotal trials outside the U.S. (South Africa, Canada, Georgia, UK, EU); the FDA may impose conditions on or decline to accept foreign trial data, jeopardizing approval of DM199.
“The initial investigator-sponsored PE trial is being conducted in South Africa, we are commencing a PE trial in Canada and we are currently globally expanding our ReMEDy2 trial to countries outside the United States.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Catalent Pharma Solutions, LLC
“We rely on Catalent Pharma Solutions, LLC (Catalent), a contract development and manufacturing organization (CDMO) with proven GMP experience in the manufacturing of recombinant proteins for clinical trials, for procuring all of our required raw materials and producing active pharmaceutical ingredient for our clinical trials.”
Cited →Catalent Pharma Solutions, LLC
“We have licensed certain gene expression technology from and we contract with Catalent for the manufacture of DM199 drug substance.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch